Actinium Pharmaceuticals received a notice from the NYSE American indicating non-compliance with Section 1003(a)(ii) of the Company Guide. The company failed to maintain the required $4.0 million in stockholders' equity, reporting approximately $2.3 million as of March 31, 2026. The company has until June 26, 2026, to submit a compliance plan to the exchange. If the plan is accepted, the company has until November 27, 2027, to regain compliance. The company's common stock continues to trade under the symbol ATNM with a .BC indicator.